C9orf72 and amyotrophic lateral sclerosis: An antisense oligonucleotide targeting C9orf72 ALS, WVE-004, showed promise in preclinical examination, however, development was recently canceled after a phase I/II clinical trial failed to show benefit compared to a placebo [161,162].